Compare Robinhood Markets, Inc. (HOOD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Neurocrine Biosciences Inc — how do they compare? Robinhood Markets, Inc. trades at $109.14 (market cap $96.21B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Robinhood Markets, Inc. is far larger — about 6.7× Neurocrine Biosciences Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HOOD | NBIX | |
|---|---|---|
Market Cap | $96.21B | $14.36B |
Volume | 22,572,153 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $152.46 | $185.50 |
52-Week Low | $65.16 | $123.10 |
Typical Hold Time | 75 Days | 23 Days |
Enterprise Value | $102.75B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $109.02, down 0.45% on the day, with a bullish technical signal and strong support at $105. The company reported robust 2025 results with revenue of $4.47B and net income of $1.88B, though valuation ratios like a P/E of 47.35 remain elevated. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at driving growth.
The outlook is positive with a consensus price target of $137.53, implying 26% upside, supported by analyst optimism and product innovation. Key risks include high valuation sensitivity, competitive pressures, and regulatory scrutiny over new offerings like leveraged crypto trading, which could impact investor sentiment and stock performance.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
